JANX vs. RVMD, LNTH, LEGN, TGTX, BBIO, AXSM, TLX, BPMC, GRFS, and NUVL
Should you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), TG Therapeutics (TGTX), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Grifols (GRFS), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.
Janux Therapeutics vs.
Janux Therapeutics (NASDAQ:JANX) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.
Revolution Medicines has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Revolution Medicines' return on equity.
Revolution Medicines received 51 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 76.61% of users gave Revolution Medicines an outperform vote while only 70.97% of users gave Janux Therapeutics an outperform vote.
Janux Therapeutics has a beta of 3.23, meaning that its stock price is 223% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.
75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 29.4% of Janux Therapeutics shares are held by company insiders. Comparatively, 8.0% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Janux Therapeutics presently has a consensus target price of $92.44, suggesting a potential upside of 198.11%. Revolution Medicines has a consensus target price of $66.31, suggesting a potential upside of 73.99%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Janux Therapeutics is more favorable than Revolution Medicines.
Janux Therapeutics has higher revenue and earnings than Revolution Medicines. Janux Therapeutics is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
In the previous week, Revolution Medicines had 6 more articles in the media than Janux Therapeutics. MarketBeat recorded 11 mentions for Revolution Medicines and 5 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 1.06 beat Revolution Medicines' score of 0.65 indicating that Janux Therapeutics is being referred to more favorably in the media.
Summary
Janux Therapeutics beats Revolution Medicines on 11 of the 19 factors compared between the two stocks.
Get Janux Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Janux Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:JANX) was last updated on 3/25/2025 by MarketBeat.com Staff
